Clinical Trials Logo

Primary Systemic Amyloidosis clinical trials

View clinical trials related to Primary Systemic Amyloidosis.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01728259 Terminated - Clinical trials for Primary Systemic Amyloidosis

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

Start date: March 2013
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of pomalidomide and bortezomib when given together with dexamethasone in treating patients with amyloid light-chain amyloidosis or light chain deposition disease. Biological therapies, such as pomalidomide, may stimulate the immune system in different ways and stop abnormal cells from growing. Bortezomib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth. Giving pomalidomide and bortezomib together with dexamethasone may be an effective treatment for amyloid light-chain amyloidosis or light chain deposition disease

NCT ID: NCT00030381 Terminated - Clinical trials for Primary Systemic Amyloidosis

Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis

Start date: December 2001
Phase: Phase 1
Study type: Interventional

Iododoxorubicin may dissolve protein deposits and be an effective treatment for primary systemic amyloidosis. Phase I trial to determine the effectiveness of iododoxorubicin in treating patients who have primary systemic amyloidosis